Pasithea Therapeutics Corp. (KTTA)
0.49
0.00 (0.00%)
USD |
NASDAQ |
Oct 22, 10:15
Pasithea Therapeutics Net Income (Quarterly) : -5.274M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -5.274M |
| March 31, 2026 | -2.870M |
| December 31, 2025 | -10.11M |
| September 30, 2025 | -3.037M |
| June 30, 2025 | -3.716M |
| March 31, 2025 | -3.563M |
| December 31, 2024 | -3.178M |
| September 30, 2024 | -3.000M |
| June 30, 2024 | -3.866M |
| March 31, 2024 | -3.861M |
| December 31, 2023 | -5.031M |
| September 30, 2023 | -3.613M |
| Date | Value |
|---|---|
| June 30, 2023 | -3.598M |
| March 31, 2023 | -3.266M |
| December 31, 2022 | -4.053M |
| September 30, 2022 | -4.191M |
| June 30, 2022 | -2.190M |
| March 31, 2022 | -1.294M |
| December 31, 2021 | 0.6301M |
| September 30, 2021 | -1.526M |
| June 30, 2021 | -0.7279M |
| March 31, 2021 | -0.5496M |
| September 30, 2020 | -0.014M |
| June 30, 2020 | 0.00 |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 5.274M |
| EPS Diluted (Quarterly) | -0.1643 |
| Enterprise Value | -29.47M |
| Earnings Yield | -322.4% |
| Normalized Earnings Yield | -327.20 |